US OptionsDetailed Quotes
NVS241018P115000
- 1.45
- -0.13-8.23%
15min DelayClose Sep 27 16:00 ET
1.50High1.35Low
1.50Open1.58Pre Close7 Volume1.36K Open Interest115.00Strike Price1.02KTurnover18.82%IV1.78%PremiumOct 18, 2024Expiry Date0.00Intrinsic Value100Multiplier19DDays to Expiry1.45Extrinsic Value100Contract SizeAmericanOptions Type-0.4238Delta0.0785Gamma72.26Leverage Ratio-0.0451Theta-0.0229Rho-30.62Eff Leverage0.1048Vega
Novartis AG Stock Discussion
Sign in to post a comment
Buying Esperion ESPR Now is Like Buying NVIDIA, TESLA,META,AMD,AAPL Before their share prices Rocketed 3000%+.
$Esperion Therapeutics (ESPR.US)$Is going to be one of those stocks people wish they loaded up on. This isn't a Pump article. Read the facts & decide for yourself. People mostly miss out the the explosive growth curve. Esperion...
$Esperion Therapeutics (ESPR.US)$Is going to be one of those stocks people wish they loaded up on. This isn't a Pump article. Read the facts & decide for yourself. People mostly miss out the the explosive growth curve. Esperion...
+15
19
3
Buying Esperion ESPR Now is Like Buying NVIDIA, TESLA,META,AMD,AAPL Before their share prices Rocketed 3000%+.
$Esperion Therapeutics (ESPR.US)$Is going to be one of those stocks you wish you had bought. Esperion is HUGELY Undervalued, company sells the ONLY statin alternative drugs with New FDA approved Primary Prevention Labels in 2024. Insurance companies are j...
$Esperion Therapeutics (ESPR.US)$Is going to be one of those stocks you wish you had bought. Esperion is HUGELY Undervalued, company sells the ONLY statin alternative drugs with New FDA approved Primary Prevention Labels in 2024. Insurance companies are j...
7
1
The Federal Reserve on Wednesday implemented its first rate cut in over four years, reducing the benchmark rate by 50 basis points to a range of 4.75%-5%.
The move surpassed Wall Street's expectations. Analysts had generally anticipated a 25 basis point cut, while the futures market had priced in a 61% probability of a 50 basis point cut and a 39% probability of a 25 basis point reduction.
Market Response to First Rate Cut
St...
The move surpassed Wall Street's expectations. Analysts had generally anticipated a 25 basis point cut, while the futures market had priced in a 61% probability of a 50 basis point cut and a 39% probability of a 25 basis point reduction.
Market Response to First Rate Cut
St...
+7
73
8
Morning Movers
Gapping up
$Williams-Sonoma (WSM.US)$ The home furnishing company saw its shares increase by 2.8% following an upgrade from Jefferies to 'buy' from 'hold.' Jefferies highlighted "hidden gems" in the company's portfolio that could benefit from even a modest recovery in the housing market.
$Viking Therapeutics (VKTX.US)$ Shares of the biotech company soared more than 4.2% as JPMorgan initiated coverage with an 'overweight'...
Gapping up
$Williams-Sonoma (WSM.US)$ The home furnishing company saw its shares increase by 2.8% following an upgrade from Jefferies to 'buy' from 'hold.' Jefferies highlighted "hidden gems" in the company's portfolio that could benefit from even a modest recovery in the housing market.
$Viking Therapeutics (VKTX.US)$ Shares of the biotech company soared more than 4.2% as JPMorgan initiated coverage with an 'overweight'...
31
1
Morning Movers
Gapping up
$Autodesk (ADSK.US)$ Shares rose by 0.8% following the software group's impressive second-quarter results, which were predominantly above consensus forecasts. The company's recent outlook upgrade also suggests strong business momentum.
$Tesla (TSLA.US)$ Shares increased by 1.2% as the electric vehicle manufacturer reported its best sales month of the year in China for August, driven by strong demand in s...
Gapping up
$Autodesk (ADSK.US)$ Shares rose by 0.8% following the software group's impressive second-quarter results, which were predominantly above consensus forecasts. The company's recent outlook upgrade also suggests strong business momentum.
$Tesla (TSLA.US)$ Shares increased by 1.2% as the electric vehicle manufacturer reported its best sales month of the year in China for August, driven by strong demand in s...
24
1
$Novartis AG (NVS.US)$
On Monday, a Delaware court denied the Swiss pharma giant's attempt for a preliminary injunction to block MSN Pharmaceuticals from launching their generic version on the U.S. market. 2024 guidance doesn't currently account for any generic releases of its best-selling drug Entresto in the U.S., the analysts say. "Should a generic Entresto get to the U.S. market, it would put about 1.5 billion U...
On Monday, a Delaware court denied the Swiss pharma giant's attempt for a preliminary injunction to block MSN Pharmaceuticals from launching their generic version on the U.S. market. 2024 guidance doesn't currently account for any generic releases of its best-selling drug Entresto in the U.S., the analysts say. "Should a generic Entresto get to the U.S. market, it would put about 1.5 billion U...
The earnings season is picking up speed, and this mid-July, we're about to get updates from some of the biggest names across various industries. Expect to hear from large banks, healthcare companies, airlines, and some of the tech and telecom giants that we all know.
The season started off last Friday with $JPMorgan (JPM.US)$ , $Wells Fargo & Co (WFC.US)$ , and $Wells Fargo & Co (WFC.US)$ sharing their numbers. They all did bett...
The season started off last Friday with $JPMorgan (JPM.US)$ , $Wells Fargo & Co (WFC.US)$ , and $Wells Fargo & Co (WFC.US)$ sharing their numbers. They all did bett...
+3
25
Keep an eye on these recently announced M&As: 👀
$Merck & Co (MRK.US)$ to acquire EyeBio
$Biogen (BIIB.US)$ to acquire HI-Bio™
$Johnson & Johnson (JNJ.US)$ to acquire Proteologix
OnKure, Inc. merger with $Reneo Pharmaceuticals (RPHM.US)$
$Novartis AG (NVS.US)$ to acquire Mariana Oncology
What companies will be next? 🤔
$Merck & Co (MRK.US)$ to acquire EyeBio
$Biogen (BIIB.US)$ to acquire HI-Bio™
$Johnson & Johnson (JNJ.US)$ to acquire Proteologix
OnKure, Inc. merger with $Reneo Pharmaceuticals (RPHM.US)$
$Novartis AG (NVS.US)$ to acquire Mariana Oncology
What companies will be next? 🤔
6
$Esperion Therapeutics (ESPR.US)$ Multiple sources indicate that Esperion's advancements and commercial success with its cholesterol-lowering drugs, NEXLIZET and NEXLETOL, have positioned it as defininte acquistion target for larger pharmaceutical companies. Esperion's drugs NEXLIZET and NEXLETOL now have primary prevention labels, NEXLIZET will soon become the drug of choice over a PCSK9 inhibitor says Texas based HeartPlace leading Cardio...
12
Stories you might have missed ![]()
Singapore’s private home sales down nearly half in February; 149 condos sold amid holiday lull
DEVELOPERS in Singapore sold 149 private homes in February, 47 per cent fewer than the 281 units moved in January, data released on Friday (Mar 15) by the Urban Redevelopment Authority showed.
Novartis invests US$256 million to expand Singapore plant
SWISS biopharma giant Novartis has invested US$256 million to expand its biopharm...
Singapore’s private home sales down nearly half in February; 149 condos sold amid holiday lull
DEVELOPERS in Singapore sold 149 private homes in February, 47 per cent fewer than the 281 units moved in January, data released on Friday (Mar 15) by the Urban Redevelopment Authority showed.
Novartis invests US$256 million to expand Singapore plant
SWISS biopharma giant Novartis has invested US$256 million to expand its biopharm...
7
No comment yet
ひな☆彡 SOXL : You convinced me. I am happy to buy some later.
Growth Investor27 : Long ESPR $1.61 is very cheap.
Growth Investor27 : Long150,000 will hold for 5x upside for 2025 if not aquired.